Radium Ra 223 dichloride is a radiopharmaceutical agent used to treat patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles.
- Mechanism
- Curator reviewed
Radium Ra 223 Dichloride is the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. The high energy damages bone cells by introducing double-stranded DNA breaks. This leads to cell death and prevention of the spread of the bone cancer cells. As well because of the alpha particle's short range of less than 10 cell diameters, its damaging effects would less likely affect the non-cancerous cells nearby.
- Primary indication
- Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.Curator reviewed · 1 structured indication
- Formula / weight
- Cl2Ra · 293.924 g/mol (avg)
- First approval
- United States, 2013 · European Union, 2016
- Also known as
- Radium (Ra-223) dichloride · Radium 223 dichloride · Radium chloride Ra-223 · Radium Ra-223 dichloride · Radium-223 chloride
- Code names
- BAY 88-8223
- Brand names
Resolves to
RWRDJVNMSZYMDV-SIUYXFDKSA-LSMILES[Cl-].[Cl-].[223Ra++]What you can answer from here — as of July 03, 2026
Which other approved drugs treat the same conditions as Radium Ra 223 dichloride, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account